nAMD and DME Treatments: Increasing the Longevity is organized by Healio, Vindico Medical Education
Release Date: August 31, 2023
Expiration Date: August 30, 2024
Activity Description:
Standard-of-care intravitreal therapies in the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) have demonstrated significant visual acuity improvements with frequent dosing. However, treatment burden has been associated with a lack of patient adherence to treatment regimens—resulting in suboptimal outcomes. The refinement of current treatment protocols, along with the integration of novel delivery systems and newer agents that offer longer durability of efficacy, are addressing the treatment burden through the extension of dosing intervals. Long-acting corticosteroid therapy is also an effective option for DME but is often not effectively integrated into management protocols. In this CE activity, experts in the field will evaluate treatment protocols that extend dosing intervals while improving outcomes in nAMD and DME through the analysis of efficacy, safety, and durability data.
Learning Objective:
Upon successful completion of this activity, participants should be better able to:
• Differentiate treatment protocols for their ability to extend intervals and improve outcomes for patients with nAMD and DME.
• Utilize treatment protocols that offer increased efficacy, safety, and durability for patients with nAMD and DME.